Expand PVLA Menu
PVLA MENU

PVLA Latest Press Releases

-- March 2, 2026 --

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares Globe Newswire 7:30 AM

-- February 25, 2026 --

Palvella Therapeutics Announces Pricing of Upsized Public Offering Globe Newswire 7:57 PM

-- February 24, 2026 --

Palvella Therapeutics Announces Proposed Public Offering Globe Newswire 4:05 PM
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations Globe Newswire 6:30 AM

-- February 23, 2026 --

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations Globe Newswire 5:00 PM

-- February 2, 2026 --

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis Globe Newswire 7:30 AM

-- January 9, 2026 --

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies Globe Newswire 7:30 AM

-- January 7, 2026 --

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs Globe Newswire 7:30 AM

-- December 16, 2025 --

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Angiokeratomas Globe Newswire 7:30 AM

-- December 15, 2025 --

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies Globe Newswire 6:00 AM

-- November 11, 2025 --

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- November 6, 2025 --

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference Globe Newswire 7:30 AM

-- November 5, 2025 --

Palvella Therapeutics Announces New QTORIN Product Candidate, QTORIN Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies Globe Newswire 6:00 AM

-- November 4, 2025 --

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025 Globe Newswire 7:30 AM

-- October 13, 2025 --

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN Rapamycin for Microcystic Lymphatic Malformations Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes